Compare · AKYA vs BIO
AKYA vs BIO
Side-by-side comparison of Akoya BioSciences Inc. (AKYA) and Bio-Rad Laboratories Inc. (BIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKYA and BIO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $8.36B, about 21.5x AKYA ($388.8M).
- Over the past year, AKYA is up 5.3% and BIO is up 43.9% - BIO leads by 38.6 points.
- BIO has hit the wire 1 time in the past 4 weeks while AKYA has been quiet.
- AKYA has more recent analyst coverage (13 ratings vs 12 for BIO).
- Company
- Akoya BioSciences Inc.
- Bio-Rad Laboratories Inc.
- Price
- $1.30-5.80%
- $311.89-1.93%
- Market cap
- $388.8M
- $8.36B
- 1M return
- +11.11%
- +13.38%
- 1Y return
- +5.26%
- +43.89%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 1980
- News (4w)
- 0
- 1
- Recent ratings
- 13
- 12
Akoya BioSciences Inc.
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. The company offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. It provides two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational, and clinical research. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Latest AKYA
- SEC Form 15-12G filed by Akoya BioSciences Inc.
- SEC Form EFFECT filed by Akoya BioSciences Inc.
- Director Mendel Scott disposed of 28,500 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Ramachandran Niro Ph.D acquired 62,566 shares, covered exercise/tax liability with 42,148 shares and disposed of 282,555 shares, closing all direct ownership in the company (SEC Form 4)
- President and CEO Mckelligon Brian disposed of 947,688 shares, acquired 724,428 shares and covered exercise/tax liability with 196,866 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Legal Officer Kamocsay Jennifer disposed of 179,272 shares, closing all direct ownership in the company (SEC Form 4)
- CFO Ek John Frederick disposed of 268,202 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Clinical Officer Bamford Pascal disposed of 205,738 shares, closing all direct ownership in the company (SEC Form 4)
- Director Winkler Matthew disposed of 984,513 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Shepler Robert G
Latest BIO
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
- Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
- Bio-Rad Reports Third-Quarter 2025 Financial Results
- Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025